The Novosibirsk Angioline plant has resumed production of stents for patients…

The founders and real leaders of the company, previously deprived of their positions by judicial lawlessness, Andrey Kudryashov and Alexey Frantsuzov, returned to Angioline. But so far everything rests only on the “honest” word of officials who count on a fair resolution of what they consider to be an ordinary corporate conflict. In fact, this dispute has long gone beyond the boundaries of one plant, and the vital domestic production of stents for heart patients is under threat of complete elimination. An alternative is American stents for the price of an airplane wing per piece.

The unlawful actions of “investment consultant” Natalya Lebedeva and shareholders from Luxembourg will be considered on July 21 in the Court of Cassation. There is a chance that the unprecedentedly absurd decision of the lower court to exclude its creators and owners of 75% of the shares from the company will be canceled – in essence, this was the transfer of Angioline to Lebedeva and foreign shareholders. Now everything can return to its previous stable and healthy course: Kudryashov and Frantsuzov will take management and the 75% of the company’s shares that rightfully belong to them into their own hands. Then the uninterrupted production of drugs for heart patients will be established, and Russian patients will have access to high-quality stents at an adequate price.

The Federal Tax Service also recently gave unambiguous hints about the need to return everything back. The tax office refused to register Lebedeva as the general director of Angioline. This gave hope for a positive resolution to the problem. But the fate of the unique stent production still hangs in the balance. Will it be possible to maintain unique domestic production or will import substitution result in failure?